RESUMEN
The accurate detection and precise assessment of therapeutic responses is critical to the optimal management of patients with lymphoma. Over the past 50 years, dramatic advances in technology have established imaging as the cornerstone of disease evaluation. However, the appropriate application of current techniques requires acknowledgement of their strengths and weaknesses, and appreciation of the full diversity of lymphoid neoplasms. The role of anatomical and functional imaging in detection, treatment escalation/de-escalation and prognostication of patients with lymphoma can be misinterpreted. The development of disease assessment criteria, without an appreciation of the limitations of current imaging technologies, reflects a potential overreach of imaging science. Furthermore, the introduction of various novel therapies adds to the complexity of disease monitoring. In this Perspectives, the authors evaluate the available evidence in this rapidly evolving field and propose a reporting framework, named 'Specialist Integrated Haematological Malignancy Imaging Reporting' (SIHMIR), with a goal of providing a robust and adaptable system for lymphoma assessment. We predict a future model of multimodal disease assessment using novel molecular and imaging techniques, and highlight the key outstanding research questions in this field.
Asunto(s)
Linfoma/diagnóstico , Linfoma/patología , Estadificación de Neoplasias/tendencias , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Linfoma/terapia , Imagen por Resonancia Magnética , Monitoreo Fisiológico/historia , Monitoreo Fisiológico/métodos , Imagen Multimodal , Estadificación de Neoplasias/historia , Estadificación de Neoplasias/métodos , Pronóstico , Tomografía Computarizada por Rayos XAsunto(s)
Corticoesteroides/uso terapéutico , Antirreumáticos/uso terapéutico , Productos Biológicos/uso terapéutico , Lactancia Materna , Complicaciones del Embarazo/tratamiento farmacológico , Enfermedades Reumáticas/tratamiento farmacológico , Corticoesteroides/administración & dosificación , Corticoesteroides/efectos adversos , Antirreumáticos/administración & dosificación , Antirreumáticos/efectos adversos , Productos Biológicos/administración & dosificación , Productos Biológicos/efectos adversos , Esquema de Medicación , Prescripciones de Medicamentos/normas , Medicina Basada en la Evidencia/métodos , Femenino , Humanos , Intercambio Materno-Fetal , EmbarazoAsunto(s)
Analgésicos/uso terapéutico , Lactancia Materna , Complicaciones del Embarazo/tratamiento farmacológico , Enfermedades Reumáticas/tratamiento farmacológico , Analgésicos/administración & dosificación , Analgésicos/efectos adversos , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Anticoagulantes/uso terapéutico , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Antihipertensivos/uso terapéutico , Esquema de Medicación , Prescripciones de Medicamentos/normas , Medicina Basada en la Evidencia/métodos , Femenino , Humanos , Intercambio Materno-Fetal , EmbarazoRESUMEN
BACKGROUND: DNA CpG methylation is carried out by DNA methyltransferases and induces chromatin remodeling and gene silencing through a transcription repressor complex comprising the methyl-CpG-binding protein 2 (MeCP2) and a subset of histone deacetylases. Recently, we have found that MeCP2 activity had a crucial role in the pattern of gene expression seen in the superficial dorsal horn rapidly after injection of Complete Freund's Adjuvant (CFA) in the rat ankle joint. The aim of the present study was to analyse the changes in expression of MeCP2, DNA methyltransferases and a subset of histone deacetylases in the superficial dorsal horn during the maintenance phase of persistent pain states. In this process, the cell specific expression of MeCP2 was also investigated. RESULTS: Using immunohistochemistry, we found that neurones, oligodendrocytes and astrocytes expressed MeCP2. Microglia, oligodendrocyte precursor cells and Schwann cells never showed any positive stain for MeCP2. Quantitative analyses showed that MeCP2 expression was increased in the superficial dorsal horn 7 days following CFA injection in the ankle joint but decreased 7 days following spared nerve injury. Overall, the expression of DNA methyltransferases and a subset of histone deacetylases followed the same pattern of expression. However, there were no significant changes in the expression of the MeCP2 targets that we had previously shown are regulated in the early time points following CFA injection in the ankle joint. Finally, the expression of MeCP2 was also down regulated in damaged dorsal root ganglion neurones following spared nerve injury. CONCLUSION: Our results strongly suggest that changes in chromatin compaction, regulated by the binding of MeCP2 complexes to methylated DNA, are involved in the modulation of gene expression in the superficial dorsal horn and dorsal root ganglia during the maintenance of persistent pain states.